Since our study demonstrated the important role of the FTO/FAP/FAK axis in NSCLC metastasis, targeting the FTO/FAP/FAK axis with selective inhibitors may be an appealing therapeutic focus for NSCLC patients. The gene discussed is FTO; the disease is non-small cell lung carcinoma.